Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 October 2018Website:
http://kodiak.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:57:02 GMTDividend
Analysts recommendations
Institutional Ownership
KOD Latest News
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New York Goldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, Florida A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
Kodiak (KOD) announces strong first-quarter 2024 results and shares progress on its pipeline development strategies.
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
- 1(current)
What type of business is Kodiak Sciences?
Kodiak Sciences Inc. is an independent biopharmaceutical company engaged in research, development, and commercialization of innovative biopharmaceutical drugs for the treatment of common eye diseases. Founded in June 2009, it is headquartered in Palo Alto, California. Kodiak Sciences Inc. does not have any developed drugs approved for commercial sale, and the company does not generate revenue from their sale. The company does not expect to generate revenue from sales until it completes development and clinical trials and receives regulatory approval for commercial sale of the developed drugs.
What sector is Kodiak Sciences in?
Kodiak Sciences is in the Healthcare sector
What industry is Kodiak Sciences in?
Kodiak Sciences is in the Biotechnology industry
What country is Kodiak Sciences from?
Kodiak Sciences is headquartered in United States
When did Kodiak Sciences go public?
Kodiak Sciences initial public offering (IPO) was on 04 October 2018
What is Kodiak Sciences website?
https://kodiak.com
Is Kodiak Sciences in the S&P 500?
No, Kodiak Sciences is not included in the S&P 500 index
Is Kodiak Sciences in the NASDAQ 100?
No, Kodiak Sciences is not included in the NASDAQ 100 index
Is Kodiak Sciences in the Dow Jones?
No, Kodiak Sciences is not included in the Dow Jones index
When does Kodiak Sciences report earnings?
The next expected earnings date for Kodiak Sciences is 14 August 2024